Literature DB >> 16971082

A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.

Ming Zhao1, Michelle A Rudek, Aleksandr Mnasakanyan, Carol Hartke, Roberto Pili, Sharyn D Baker.   

Abstract

A rapid, sensitive and selective method was developed and validated using LC/MS/MS for determination of MS-275 in human plasma. Sample preparation involved a single step liquid-liquid extraction by the addition of 0.2 ml of plasma with 5 ml acetonitrile/n-butyl-chloride. Separation of the compounds of interest, including the internal standard paclitaxel, was achieved on a Waters X-Terra C(18) (50 mm x 2.1mm i.d., 3.5 microm) analytical column using a mobile phase consisting of acetonitrile/ammonium acetate (pH 2.9; 2mM)(60:40, v/v) containing 0.1% formic acid and isocratic flow at 0.15 ml/min for 3 min. The analytes were monitored by tandem-mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 0.5-100 ng/ml with values for the coefficient of determination of >0.99. The values for both within day and between day precision and accuracy were well within the generally accepted criteria for analytical methods (<15%). This method was subsequently used to measure concentrations of MS-275 in cancer patients receiving an oral weekly dose of 4 mg/m(2).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971082      PMCID: PMC1797151          DOI: 10.1016/j.jpba.2006.08.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

Authors:  Jerry Jaboin; Jason Wild; Habib Hamidi; Chand Khanna; Chong Jai Kim; Robert Robey; Susan E Bates; Carol J Thiele
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

2.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Authors:  A Saito; T Yamashita; Y Mariko; Y Nosaka; K Tsuchiya; T Ando; T Suzuki; T Tsuruo; O Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

Review 3.  Rational development of histone deacetylase inhibitors as anticancer agents: a review.

Authors:  Milin R Acharya; Alex Sparreboom; Jürgen Venitz; William D Figg
Journal:  Mol Pharmacol       Date:  2005-06-14       Impact factor: 4.436

Review 4.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

Authors:  P A Marks; V M Richon; R A Rifkind
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

5.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

Authors:  Qin C Ryan; Donna Headlee; Milin Acharya; Alex Sparreboom; Jane B Trepel; Joseph Ye; William D Figg; Kyunghwa Hwang; Eun Joo Chung; Anthony Murgo; Giovanni Melillo; Yusri Elsayed; Manish Monga; Mikhail Kalnitskiy; James Zwiebel; Edward A Sausville
Journal:  J Clin Oncol       Date:  2005-04-25       Impact factor: 44.544

6.  Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

Authors:  Kyunghwa Hwang; Milin R Acharya; Edward A Sausville; Suoping Zhai; Eunhee W Woo; Jürgen Venitz; William D Figg; Alex Sparreboom
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-05-25       Impact factor: 3.205

  6 in total
  7 in total

1.  Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.

Authors:  Roisin M Connolly; Huili Li; Rachel C Jankowitz; Zhe Zhang; Michelle A Rudek; Stacie C Jeter; Shannon A Slater; Penny Powers; Antonio C Wolff; John H Fetting; Adam Brufsky; Richard Piekarz; Nita Ahuja; Peter W Laird; Hui Shen; Daniel J Weisenberger; Leslie Cope; James G Herman; George Somlo; Agustin A Garcia; Peter A Jones; Stephen B Baylin; Nancy E Davidson; Cynthia A Zahnow; Vered Stearns
Journal:  Clin Cancer Res       Date:  2016-12-15       Impact factor: 12.531

2.  ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

Authors:  Connie Lee Batlevi; Yvette Kasamon; R Gregory Bociek; Peter Lee; Lia Gore; Amanda Copeland; Rachel Sorensen; Peter Ordentlich; Scott Cruickshank; Lori Kunkel; Daniela Buglio; Francisco Hernandez-Ilizaliturri; Anas Younes
Journal:  Haematologica       Date:  2016-05-05       Impact factor: 9.941

3.  Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection.

Authors:  Matthew Danish; Erin R Gardner; Xiaohong Chen; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-13       Impact factor: 3.205

4.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Authors:  Rosalyn A Juergens; John Wrangle; Frank P Vendetti; Sara C Murphy; Ming Zhao; Barbara Coleman; Rosa Sebree; Kristen Rodgers; Craig M Hooker; Noreli Franco; Beverly Lee; Salina Tsai; Igor Espinoza Delgado; Michelle A Rudek; Steven A Belinsky; James G Herman; Stephen B Baylin; Malcolm V Brock; Charles M Rudin
Journal:  Cancer Discov       Date:  2011-11-09       Impact factor: 39.397

5.  Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

Authors:  R Pili; B Salumbides; M Zhao; S Altiok; D Qian; J Zwiebel; M A Carducci; M A Rudek
Journal:  Br J Cancer       Date:  2011-12-01       Impact factor: 7.640

6.  "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.

Authors:  Andrea Savarino; Antonello Mai; Sandro Norelli; Sary El Daker; Sergio Valente; Dante Rotili; Lucia Altucci; Anna Teresa Palamara; Enrico Garaci
Journal:  Retrovirology       Date:  2009-06-02       Impact factor: 4.602

7.  Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).

Authors:  Evanthia T Roussos Torres; Christine Rafie; Chenguang Wang; David Lim; Adam Brufsky; Patricia LoRusso; Joseph Paul Eder; Vincent Chung; Melinda Downs; Molly Geare; Richard Piekarz; Howard Streicher; Leslie Anforth; Michelle A Rudek; Qingfeng Zhu; Sepideh Besharati; Ashley Cimino-Mathews; Robert A Anders; Vered Stearns; Elizabeth M Jaffee; Roisin M Connolly
Journal:  Clin Cancer Res       Date:  2021-06-16       Impact factor: 12.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.